title: Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye.
abstract: OBJECTIVE
  To determine the effect of rebamipide ophthalmic suspension on optical quality in patients with dry eye with short break-up time (BUT) of the tear film.
  
  
  METHODS
  Twenty-six eyes of 16 patients with the short BUT type of dry eye were enrolled and treated with 2% rebamipide ophthalmic suspension. At baseline and at 2 and 4 weeks after initiating the treatment, the serial corneal higher-order aberrations (HOAs), BUT, fluorescein staining, and Schirmer test were measured. Patients were asked to complete questionnaires about the changes in dry eye-related ocular symptoms after the treatment.
  
  
  RESULTS
  Before the treatment, the pattern of postblink corneal HOAs for 10 seconds showed a sawtooth pattern, with a marked upward curve that increased after blinking. Treatment with rebamipide for 4 weeks significantly (P < 0.05) improved the postblink corneal HOAs and stabilized the pattern of the corneal HOAs. Significant increases in the tear film BUT were seen 2 and 4 weeks after the treatment (P < 0.001 for both comparisons).
  
  
  CONCLUSIONS
  Rebamipide administered to treat the short BUT type of dry eye significantly improved optical quality because of the improvement in tear stability.
authors.affiliation: Department of Ophthalmology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan. skoh@ophthal.med.osaka-u.ac.jp
authors.forename: Shizuka
authors.initials: S
authors.lastname: Koh
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Inoue
authors.forename: Toshiki
authors.initials: T
authors.lastname: Sugmimoto
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Maeda
authors.forename: Kohji
authors.initials: K
authors.lastname: Nishida
mesh_terms: D057128:Aberrometry; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D019781:Corneal Topography; D057108:Corneal Wavefront Aberration / Q000503:physiopathology; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D013666:Tears / Q000378:metabolism*; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D000975:Antioxidants; D009883:Ophthalmic Solutions; D015363:Quinolones; C052785:rebamipide; D000409:Alanine